Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 95

1.

Mirodenafil for the treatment of erectile dysfunction: a systematic review of the literature.

Park HJ, Moon KH, Lee SW, Lee WK, Kam SC, Lee JH, Park NC.

World J Mens Health. 2014 Apr;32(1):18-27. doi: 10.5534/wjmh.2014.32.1.18. Epub 2014 Apr 25. Review.

PMID:
24872948
[PubMed]
Free PMC Article
2.

An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors.

Bruzziches R, Francomano D, Gareri P, Lenzi A, Aversa A.

Expert Opin Pharmacother. 2013 Jul;14(10):1333-44. doi: 10.1517/14656566.2013.799665. Epub 2013 May 16. Review.

PMID:
23675780
[PubMed - indexed for MEDLINE]
3.

Avanafil for the treatment of erectile dysfunction: initial data and clinical key properties.

Kedia GT, Uckert S, Assadi-Pour F, Kuczyk MA, Albrecht K.

Ther Adv Urol. 2013 Feb;5(1):35-41. doi: 10.1177/1756287212466282.

PMID:
23372609
[PubMed]
Free PMC Article
4.

Comparison of phosphodiesterase type 5 (PDE5) inhibitors.

Wright PJ.

Int J Clin Pract. 2006 Aug;60(8):967-75. Epub 2006 Jun 16. Review. Erratum in: Int J Clin Pract. 2006 Nov;60(11):1517.

PMID:
16780568
[PubMed - indexed for MEDLINE]
5.

Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.

Yuan J, Zhang R, Yang Z, Lee J, Liu Y, Tian J, Qin X, Ren Z, Ding H, Chen Q, Mao C, Tang J.

Eur Urol. 2013 May;63(5):902-12. doi: 10.1016/j.eururo.2013.01.012. Epub 2013 Jan 31. Review.

PMID:
23395275
[PubMed - indexed for MEDLINE]
6.

Efficacy and safety of oral mirodenafil in the treatment of erectile dysfunction in diabetic men in Korea: a multicenter, randomized, double-blind, placebo-controlled clinical trial.

Park HJ, Choi HK, Ahn TY, Park JK, Chung WS, Lee SW, Kim SW, Hyun JS, Park NC.

J Sex Med. 2010 Aug;7(8):2842-50. doi: 10.1111/j.1743-6109.2010.01888.x. Epub 2010 Jul 7.

PMID:
20626604
[PubMed - indexed for MEDLINE]
7.

Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction.

Paick JS, Ahn TY, Choi HK, Chung WS, Kim JJ, Kim SC, Kim SW, Lee SW, Min KS, Moon KH, Park JK, Park K, Park NC, Suh JK, Yang DY, Jung HG.

J Sex Med. 2008 Nov;5(11):2672-80. doi: 10.1111/j.1743-6109.2008.00945.x. Epub 2008 Jul 14.

PMID:
18638004
[PubMed - indexed for MEDLINE]
8.

The penile erection efficacy of a new phosphodiesterase type 5 inhibitor, mirodenafil (SK3530), in rabbits with acute spinal cord injury.

Jung JY, Kim SK, Kim BS, Lee SH, Park YS, Kim SJ, Choi C, Yoon SI, Kim JS, Cho SD, Im GJ, Lee SM, Jung JW, Lee YS.

J Vet Med Sci. 2008 Nov;70(11):1199-204.

PMID:
19057138
[PubMed - indexed for MEDLINE]
Free Article
9.

Phosphodiesterase type 5 inhibitors in the management of non-neurogenic male lower urinary tract symptoms: critical analysis of current evidence.

Martínez-Salamanca JI, Carballido J, Eardley I, Giuliano F, Gratzke C, Rosen R, Salonia A, Stief C.

Eur Urol. 2011 Sep;60(3):527-35. doi: 10.1016/j.eururo.2011.05.054. Epub 2011 Jun 12. Review.

PMID:
21684677
[PubMed - indexed for MEDLINE]
10.

Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction.

Mulhall JP, McLaughlin TP, Harnett JP, Scott B, Burhani S, Russell D.

J Sex Med. 2005 Nov;2(6):848-55.

PMID:
16422809
[PubMed - indexed for MEDLINE]
11.

PDE5 inhibitors: are there differences?

Carson CC.

Can J Urol. 2006 Feb;13 Suppl 1:34-9. Review.

PMID:
16526979
[PubMed - indexed for MEDLINE]
12.

The management of erectile dysfunction: innovations and future perspectives.

Leonardi R, Alemanni M.

Arch Ital Urol Androl. 2011 Mar;83(1):60-2.

PMID:
21585174
[PubMed - indexed for MEDLINE]
13.

Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability.

Wang R, Burnett AL, Heller WH, Omori K, Kotera J, Kikkawa K, Yee S, Day WW, DiDonato K, Peterson CA.

J Sex Med. 2012 Aug;9(8):2122-9. doi: 10.1111/j.1743-6109.2012.02822.x. Epub 2012 Jul 3.

PMID:
22759639
[PubMed - indexed for MEDLINE]
14.

A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.

Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA, Roehrborn CG, Serni S, Mirone V, Carini M, Maggi M.

Eur Urol. 2012 May;61(5):994-1003. doi: 10.1016/j.eururo.2012.02.033. Epub 2012 Feb 25. Review.

PMID:
22405510
[PubMed - indexed for MEDLINE]
15.

Novel phosphodiesterase type 5 modulators: a patent survey (2008 - 2010).

Bell AS, Palmer MJ.

Expert Opin Ther Pat. 2011 Oct;21(10):1631-41. doi: 10.1517/13543776.2011.614435. Epub 2011 Sep 9. Review.

PMID:
21905762
[PubMed - indexed for MEDLINE]
16.

Looking to the future for erectile dysfunction therapies.

Hatzimouratidis K, Hatzichristou DG.

Drugs. 2008;68(2):231-50. Review.

PMID:
18197727
[PubMed - indexed for MEDLINE]
17.

Phosphodiesterase 5 inhibitors for erectile dysfunction.

Setter SM, Iltz JL, Fincham JE, Campbell RK, Baker DE.

Ann Pharmacother. 2005 Jul-Aug;39(7-8):1286-95. Epub 2005 Jun 7. Review.

PMID:
15941818
[PubMed - indexed for MEDLINE]
18.

Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men.

Gales BJ, Gales MA.

Ann Pharmacother. 2008 Jan;42(1):111-5. Epub 2007 Dec 19. Review.

PMID:
18094344
[PubMed - indexed for MEDLINE]
20.

Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study.

Hatzichristou D, Haro JM, Martin-Morales A, von Keitz A, Riley A, Bertsch J, Belger M, Wolka AM, Beardsworth A; EDOS Group.

Int J Clin Pract. 2007 Nov;61(11):1850-62. Epub 2007 Sep 10.

PMID:
17850306
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk